Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

A dose-escalation, randomized, double-blind, placebo-controlled phase 1 clinical trial enrolled 145 eligible participants aged 18–55 years in March 2015 in Liuzhou, China. Stratified by age and sex, the participants were randomly assigned to receive either 30, 60, or 90 μg of the HPV-6/11 vaccine (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Zhao-Jun, Bi, Zhao-Feng, Sheng, Wei, Chen, Qi, Huang, Teng, Li, Ming-Qiang, Cui, Xue-Lian, Wangjiang, Ya-Hui, Lin, Bi-Zhen, Zheng, Feng-Zhu, Sun, Guang, Li, Ya-Fei, Zheng, Ya, Zhuang, Si-Jie, Su, Ying-Ying, Pan, Hui-Rong, Huang, Shou-Jie, Wu, Ting, Zhang, Jun, Xia, Ning-Shao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
HPV – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746527/
https://www.ncbi.nlm.nih.gov/pubmed/35834812
http://dx.doi.org/10.1080/21645515.2022.2092363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746527/
https://www.ncbi.nlm.nih.gov/pubmed/35834812
http://dx.doi.org/10.1080/21645515.2022.2092363

Ejemplares similares